About Anthem Biosciences Limited
Data last updated: 14 July 2026
Anthem Biosciences Limited is a public limited company based in Bangalore, Karnataka, India. It specialises in pharma contract r and d, a part of the broader pharmaceuticals sector. Incorporated on 13 June 2006, the company has been in operation for over 20 years.
Registered with ROC Bangalore under CIN U24233KA2006PLC039703. Listed.
Capital: an authorised share capital of ₹125 Cr and a paid-up capital of ₹112.68 Cr. It is led by directors including Ganesh Sambasivam and Ajay Bhardwaj.
Last AGM: 10 June 2025. Financial statements filed for year ended 31 March 2025. Office: Bangalore, Karnataka.
As per NSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹2,124.33 Cr. The net worth stands at ₹3,042.52 Cr. Total assets are valued at ₹3,429.29 Cr.
The company has a workforce of approximately 1,876 employees as per the latest available data.
The company is associated with 1 brand - Anthem Biosciences. As per MCA filings, the company has open charges of ₹311.21 Cr and satisfied charges of ₹484.38 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website anthembio.com.
-
EmailLocked
-
TelephoneLocked
-
WebsiteLocked
-
Social Media
-
Registered AddressNo. 49 F1 & F2 Canara Bank Road Bommasandra Industrial Area Phase I Bo, Mmasandra, Bangalore, Karnataka, India – 560099
-
IndustryPharma, Pharma Contract R&D
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Anthem Biosciences Limited
Anthem Biosciences Limited has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24233KA2006PLC039703, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24233KA2006PLC039703 | Current |
| U24233KA2006PTC039703 | Previous |
| U24233KA2006PLC039703 | Previous |
Associated Brands with Anthem Biosciences Limited
Anthem Biosciences Limited operates one associated brand: Anthem Biosciences. These brands represent Anthem Biosciences Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Developer of integrated contract research development and manufacturing services | anthembio.com |
Competitors & Alternatives of Anthem Biosciences Limited
Brands and companies operating in the same space as Anthem Biosciences Limited include Abzena, Syngene, Grand River Aseptic Manufacturing and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Abzena
|
Provider of antibody discovery, cell line development, and bio analytics services | Cambridge, United Kingdom, United Kingdom | 2001 |
Syngene
|
Provider of contract research and manufacturing services for both small molecules and biologics | Bengaluru, India, India | 1993 |
Grand River Aseptic Manufacturing
|
Sterile parenteral CDMO services for development and manufacturing are offered. | Grand Rapids, United States, United States | 2010 |
Patheon
|
Commercial manufacturing and pharmaceutical development services for biopharmaceutical industry | Durham, United States, United States | 1974 |
Panacea Biotec
|
Developer of biosimilars, vaccines and natural products | Ambala, India, India | 1984 |
Piramal Group
|
Multinational conglomerate with diverse interests in Pharma, Financial Services and Real Estate | Mumbai, India, India | 1984 |
Maravai Life Sciences
|
Provides enabling tools and services in the life sciences research and bio-production industries | San Diego, United States, United States | 2014 |
LakePharma
|
Provider of drug discovery on molecular biology, viral vectors and cell & protein engineering | Belmont, United States, United States | 2009 |
Insud Pharma
|
Finished formulations, APIs, and monoclonal antibodies are developed and manufactured. | Madrid, Spain, Spain | 1977 |
Business Activity of Anthem Biosciences Limited
Anthem Biosciences Limited is engaged in principal business activities including manufacturing and professional, scientific and technical, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products, scientific research and development. The company has 2 registered principal business activity segments, demonstrating its operational diversity and market reach.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
| M | Professional, Scientific and Technical | M5 | Scientific research and development | Locked |
Business activity turnover details for Anthem Biosciences Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Anthem Biosciences Limited
Anthem Biosciences Limited is audited by M/s K.P. Rao & Co. (ICAI peer reviewed, certificate valid till 2027-04-30) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| M/s K.P. Rao & Co. (ICAI peer reviewed, certificate valid till 2027-04-30) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Anthem Biosciences Limited
Anthem Biosciences Limited is currently managed by 8 directors, with 3 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Ganesh Sambasivam
Also directs:
Anthem Biosciences Limited, Neoanthem Lifesciences Private Limited, Aic Jyothy Institute Of Technology Foundation and 1 more
|
Whole-Time Director | 04 Aug 2006 | 20 Years 1 Months | Current |
| Ajay Bhardwaj | Managing Director | 13 Jun 2006 | 20 Years 2 Months | Current |
|
Shubha Kulkarni
Also directs:
Anthem Biosciences Limited, Jobsforher Restart Portal Private Limited, Altissimo Consulting And Services Private Limited and 1 more
|
Director | 27 Sep 2024 | 1 Years 11 Months | Current |
|
K Ravindra Chandrappa
Also directs:
Anthem Biosciences Limited, Neoanthem Lifesciences Private Limited, Kcr Ventures Llp and 2 more
|
Whole-Time Director | 27 Sep 2006 | 19 Years 11 Months | Current |
| Ramadurai Ramesh | Director | 27 Sep 2024 | 1 Years 11 Months | Current |
| Satish Chander Subbanna | Nominee Director | 09 Apr 2021 | 5 Years 5 Months | Current |
Financials of Anthem Biosciences Limited FY 2026 filings available
Anthem Biosciences Limited reported revenue of ₹2,124.33 Cr for FY 2026.
| Metrics | FY 2026 |
|---|---|
| Revenue from Operations | ₹2,124.33 Cr |
| Other Income | ₹155.78 Cr |
| Total Income | ₹2,280.12 Cr |
| Cost of Materials Consumed | ₹713.59 Cr |
| Purchases of Stock-in-Trade | ₹0 |
| Changes in Inventories | ₹98.69 Cr |
| Employee Benefit Expense | ₹282.71 Cr |
| Finance Costs | ₹6.89 Cr |
| Depreciation & Amortisation | ₹134.07 Cr |
| Other Expenses | ₹195.53 Cr |
| Total Expenses | ₹1,431.49 Cr |
| Profit Before Exceptional Items & Tax | ₹848.63 Cr |
| Exceptional Items | -₹24.39 Cr |
| Profit Before Tax | ₹824.24 Cr |
| Total Tax Expense | ₹232.45 Cr |
| Net Profit | ₹591.79 Cr |
| Other Comprehensive Income | -₹1.57 Cr |
| Total Comprehensive Income | ₹590.23 Cr |
| EBITDA (computed) | ₹989.59 Cr |
| Basic EPS | ₹10.55 |
| Diluted EPS | ₹10.43 |
| Metrics | FY 2026 |
|---|---|
| Total Assets | ₹3,429.29 Cr |
| Non-current Assets | ₹1,626.15 Cr |
| Current Assets | ₹1,803.14 Cr |
| Property, Plant & Equipment | ₹780.26 Cr |
| Inventories | ₹124.52 Cr |
| Trade Receivables | ₹590.59 Cr |
| Cash & Equivalents | ₹272.91 Cr |
| Equity (Net Worth) | ₹3,042.52 Cr |
| Equity Share Capital | ₹112.34 Cr |
| Borrowings (Non-current) | ₹27.73 Cr |
| Borrowings (Current) | ₹23.33 Cr |
| Total Debt (computed) | ₹51.07 Cr |
| Current Liabilities | ₹325.71 Cr |
| Total Liabilities | ₹386.77 Cr |
| Metrics | FY 2026 |
|---|---|
| Operating Cash Flow | ₹844.49 Cr |
| Investing Cash Flow | -₹701.62 Cr |
| Financing Cash Flow | -₹40 Cr |
| Capital Expenditure | ₹211.17 Cr |
| Free Cash Flow (computed) | ₹633.32 Cr |
| Dividends Paid | ₹0 |
| Net Change in Cash | ₹102.6 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|---|---|---|---|
| Revenue from Operations | ₹610.94 Cr | ₹423.15 Cr | ₹550.03 Cr | ₹540.21 Cr |
| Other Income | ₹51.21 Cr | ₹33.53 Cr | ₹48.23 Cr | ₹22.81 Cr |
| Total Income | ₹662.16 Cr | ₹456.68 Cr | ₹598.26 Cr | ₹563.02 Cr |
| Cost of Materials Consumed | ₹165.2 Cr | ₹184.92 Cr | ₹201.26 Cr | ₹162.21 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹50.25 Cr | -₹42.33 Cr | ₹22.1 Cr | ₹68.67 Cr |
| Employee Benefit Expense | ₹72.48 Cr | ₹70.48 Cr | ₹67.72 Cr | ₹72.03 Cr |
| Finance Costs | ₹1.9 Cr | ₹35.3 Lakh | ₹3.03 Cr | ₹1.61 Cr |
| Depreciation & Amortisation | ₹39.59 Cr | ₹34.53 Cr | ₹33.5 Cr | ₹26.45 Cr |
| Other Expenses | ₹55.79 Cr | ₹52.89 Cr | ₹41.05 Cr | ₹45.81 Cr |
| Total Expenses | ₹385.22 Cr | ₹300.84 Cr | ₹368.65 Cr | ₹376.77 Cr |
| Profit Before Exceptional Items & Tax | ₹276.94 Cr | ₹155.84 Cr | ₹229.6 Cr | ₹186.25 Cr |
| Exceptional Items | ₹98 Lakh | -₹25.37 Cr | ₹0 | ₹0 |
| Profit Before Tax | ₹277.92 Cr | ₹130.47 Cr | ₹229.6 Cr | ₹186.25 Cr |
| Total Tax Expense | ₹88.16 Cr | ₹37.66 Cr | ₹56.17 Cr | ₹50.46 Cr |
| Net Profit | ₹189.76 Cr | ₹92.82 Cr | ₹173.43 Cr | ₹135.79 Cr |
| attributable to Owners | - | ₹0 | ₹0 | ₹0 |
| attributable to NCI | - | ₹0 | ₹0 | ₹0 |
| Other Comprehensive Income | -₹76.6 Lakh | -₹77.9 Lakh | -₹1.55 Cr | ₹1.53 Cr |
| Total Comprehensive Income | ₹188.99 Cr | ₹92.04 Cr | ₹171.88 Cr | ₹137.32 Cr |
| EBITDA (computed) | ₹318.43 Cr | ₹190.73 Cr | ₹266.13 Cr | ₹214.3 Cr |
| Basic EPS | ₹3.38 | ₹1.65 | ₹3.09 | ₹2.43 |
| Diluted EPS | ₹3.34 | ₹1.64 | ₹3.06 | ₹2.42 |
| Segment · Q4 FY26 (latest quarter) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| CRDMO | ₹512.84 Cr | ₹343.83 Cr | ₹0 | ₹0 |
| Speciality Ingredients | ₹98.11 Cr | ₹51.66 Cr | ₹0 | ₹0 |
| Segment · FY 2026 (annual) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| CRDMO | ₹1,772.77 Cr | ₹1,132.99 Cr | - | - |
| Speciality Ingredients | ₹351.57 Cr | ₹179.07 Cr | - | - |
| Metrics | FY 2026 |
|---|---|
| Revenue from Operations | ₹2,089.31 Cr |
| Other Income | ₹182.08 Cr |
| Total Income | ₹2,271.39 Cr |
| Cost of Materials Consumed | ₹696.75 Cr |
| Purchases of Stock-in-Trade | ₹0 |
| Changes in Inventories | ₹98.69 Cr |
| Employee Benefit Expense | ₹263.92 Cr |
| Finance Costs | ₹6.55 Cr |
| Depreciation & Amortisation | ₹99.57 Cr |
| Other Expenses | ₹178.83 Cr |
| Total Expenses | ₹1,344.31 Cr |
| Profit Before Exceptional Items & Tax | ₹927.08 Cr |
| Exceptional Items | -₹24.01 Cr |
| Profit Before Tax | ₹903.07 Cr |
| Total Tax Expense | ₹232.51 Cr |
| Net Profit | ₹670.56 Cr |
| Other Comprehensive Income | -₹1.5 Cr |
| Total Comprehensive Income | ₹669.06 Cr |
| EBITDA (computed) | ₹1,033.19 Cr |
| Basic EPS | ₹11.95 |
| Diluted EPS | ₹11.82 |
| Metrics | FY 2026 |
|---|---|
| Total Assets | ₹3,530.85 Cr |
| Non-current Assets | ₹1,842.44 Cr |
| Current Assets | ₹1,688.4 Cr |
| Property, Plant & Equipment | ₹609.6 Cr |
| Inventories | ₹119.14 Cr |
| Trade Receivables | ₹572.93 Cr |
| Cash & Equivalents | ₹267.88 Cr |
| Equity (Net Worth) | ₹3,184.7 Cr |
| Equity Share Capital | ₹112.34 Cr |
| Borrowings (Non-current) | ₹28.2 Cr |
| Borrowings (Current) | ₹18.97 Cr |
| Total Debt (computed) | ₹47.17 Cr |
| Current Liabilities | ₹285.47 Cr |
| Total Liabilities | ₹346.15 Cr |
| Metrics | FY 2026 |
|---|---|
| Operating Cash Flow | ₹889.41 Cr |
| Investing Cash Flow | -₹742 Cr |
| Financing Cash Flow | -₹43.55 Cr |
| Capital Expenditure | ₹139.98 Cr |
| Free Cash Flow (computed) | ₹749.43 Cr |
| Dividends Paid | ₹0 |
| Net Change in Cash | ₹103.6 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 |
|---|---|---|---|---|
| Revenue from Operations | ₹582.5 Cr | ₹416.58 Cr | ₹552.23 Cr | ₹538.01 Cr |
| Other Income | ₹60.63 Cr | ₹39.92 Cr | ₹53.8 Cr | ₹27.73 Cr |
| Total Income | ₹643.13 Cr | ₹456.5 Cr | ₹606.03 Cr | ₹565.74 Cr |
| Cost of Materials Consumed | ₹150.07 Cr | ₹180.57 Cr | ₹203.71 Cr | ₹162.4 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹50.25 Cr | -₹42.33 Cr | ₹22.1 Cr | ₹68.67 Cr |
| Employee Benefit Expense | ₹66.73 Cr | ₹65.47 Cr | ₹63.16 Cr | ₹68.57 Cr |
| Finance Costs | ₹1.58 Cr | ₹1.13 Cr | ₹2.23 Cr | ₹1.61 Cr |
| Depreciation & Amortisation | ₹26.28 Cr | ₹26.75 Cr | ₹23.92 Cr | ₹22.61 Cr |
| Other Expenses | ₹48.46 Cr | ₹49.82 Cr | ₹37.6 Cr | ₹42.95 Cr |
| Total Expenses | ₹343.38 Cr | ₹281.4 Cr | ₹352.72 Cr | ₹366.8 Cr |
| Profit Before Exceptional Items & Tax | ₹299.75 Cr | ₹175.09 Cr | ₹253.3 Cr | ₹198.94 Cr |
| Exceptional Items | ₹97.1 Lakh | -₹24.98 Cr | ₹0 | ₹0 |
| Profit Before Tax | ₹300.72 Cr | ₹150.11 Cr | ₹253.3 Cr | ₹198.94 Cr |
| Total Tax Expense | ₹89.06 Cr | ₹37.99 Cr | ₹54.87 Cr | ₹50.6 Cr |
| Net Profit | ₹211.66 Cr | ₹112.12 Cr | ₹198.43 Cr | ₹148.34 Cr |
| Other Comprehensive Income | -₹81.8 Lakh | -₹73.3 Lakh | -₹1.45 Cr | ₹1.5 Cr |
| Total Comprehensive Income | ₹210.85 Cr | ₹111.39 Cr | ₹196.98 Cr | ₹149.84 Cr |
| EBITDA (computed) | ₹327.62 Cr | ₹202.97 Cr | ₹279.45 Cr | ₹223.16 Cr |
| Basic EPS | ₹3.77 | ₹2.00 | ₹3.54 | ₹2.65 |
| Diluted EPS | ₹3.73 | ₹1.98 | ₹3.51 | ₹2.64 |
| Segment · Q4 FY26 (latest quarter) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| CRDMO | ₹484.41 Cr | ₹330.53 Cr | ₹0 | ₹0 |
| Speciality Ingredients | ₹98.09 Cr | ₹51.64 Cr | ₹0 | ₹0 |
| Segment · FY 2026 (annual) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| CRDMO | ₹1,729.61 Cr | ₹1,110.67 Cr | - | - |
| Speciality Ingredients | ₹359.7 Cr | ₹183.2 Cr | - | - |
Board & Governance of Anthem Biosciences Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Anthem Biosciences Limited has 8 directors - 4 independent and 3 executive. The board is chaired by AJAY BHARDWAJ.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| AJAY BHARDWAJ | Executive Director · CEO-MD · Chairperson | 2006-06-13 | 1 |
| GANESH SAMBASIVAM | Executive Director | 2006-08-04 | 1 |
| K RAVINDRA CHANDRAPPA | Executive Director | 2006-09-27 | 1 |
| RAVIKANT UPPAL | Non-Executive - Independent Director | 2024-09-27 | 2 |
| SUBRAMANIAN MADHAVAN | Non-Executive - Independent Director | 2024-09-27 | 5 |
| RAMESH RAMADURAI | Non-Executive - Independent Director | 2024-09-27 | 2 |
| SHUBHA KULKARNI | Non-Executive - Independent Director | 2024-09-27 | 1 |
| SATISH CHANDER SUBBANNA | Non-Executive - Nominee Director | 2021-04-09 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | SUBRAMANIAN MADHAVAN (Chairperson), RAVIKANT UPPAL, RAMESH RAMADURAI, AJAY BHARDWAJ |
| Nomination and remuneration committee | RAVIKANT UPPAL (Chairperson), SUBRAMANIAN MADHAVAN, RAMESH RAMADURAI, SHUBHA KULKARNI |
| Stakeholders Relationship Committee | SHUBHA KULKARNI (Chairperson), RAMESH RAMADURAI, AJAY BHARDWAJ, K RAVINDRA CHANDRAPPA |
| Risk Management Committee | RAMESH RAMADURAI (Chairperson), SUBRAMANIAN MADHAVAN, AJAY BHARDWAJ, K RAVINDRA CHANDRAPPA |
| Corporate Social Responsibility Committee | AJAY BHARDWAJ (Chairperson), K RAVINDRA CHANDRAPPA, GANESH SAMBASIVAM, SHUBHA KULKARNI |
Charges & Borrowings of Anthem Biosciences Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 15 Sep 2022 | Citi Bank N.A. | ₹125 Cr | Open |
| 16 May 2017 | Hdfc Bank Limited | ₹25 Cr | Open |
| 14 Feb 2017 | Others | ₹11.21 Cr | Open |
| 26 May 2014 | Citi Bank N.A. | ₹150 Cr | Open |
| 16 Feb 2023 | Others | ₹204 Cr | Satisfied |
Total charge records: 14 View all charges
Employees and EPFO Compliance at Anthem Biosciences Limited
View historical data on people associated with Anthem Biosciences Limited, including employment history and EPFO contributions.
Employee and EPFO history for Anthem Biosciences Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Anthem Biosciences Limited
GST registrations and filing compliance for Anthem Biosciences Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Anthem Biosciences Limited
Credit ratings, litigation, and regulatory alerts for Anthem Biosciences Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Anthem Biosciences Limited
MSME payment history for Anthem Biosciences Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Anthem Biosciences Limited
Corporate group structure for Anthem Biosciences Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Anthem Biosciences Limited
MCA filings and documents for Anthem Biosciences Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Anthem Biosciences Limited
Recent News on Anthem Biosciences Limited
Frequently Asked Questions about Anthem Biosciences Limited
Anthem Biosciences Limited is an active public limited company in the pharma sector based in Bangalore, Karnataka, India. It was incorporated on 13 June 2006 (20+ years old) and is registered under CIN L24233KA2006PLC039703. The company has 1,876 employees.
Anthem Biosciences Limited reported revenue of ₹2,124.33 Cr for FY 2026 based on consolidated NSE filings.
The current directors of Anthem Biosciences Limited are:
- Ganesh Sambasivam - Whole-Time Director
- Ajay Bhardwaj - Managing Director
- Shubha Kulkarni - Director
- K Ravindra Chandrappa - Whole-Time Director
- Ramadurai Ramesh - Director
- Satish Chander Subbanna - Nominee Director
- Subramanian Madhavan - Director
- Ravikant Uppal - Director
The primary industry of Anthem Biosciences Limited is pharma. The company specifically operates in pharma contract r and d. The company is currently active in this sector.
Yes, Anthem Biosciences Limited is a listed company.
Anthem Biosciences Limited can be reached at the registered office: No. 49 F1 & F2 Canara Bank Road Bommasandra Industrial Area Phase I Bo, Mmasandra, Bangalore, Karnataka, India – 560099, or through the website anthembio.com.